Citations

Mayo Clinic

Showing 10 of 108523 citations.

PA-VSD Without MAPCA(s): Review of Long-Term Outcomes and Reinterventions
Stephens, Elizabeth H. , Dearani, Joseph A. , Miranda, William R. , Dearani, Joseph A. , Anderson, Jason H.

World Journal for Pediatric and Congenital Heart Surgery | July 23, 2024 | Volume: 16 | Issue: 2 | Pages: 232-236

10.1177/21501351241254034 | PMID 39043197 Get It

Background Pulmonary atresia with ventricular septal defect without major aortopulmonary collateral arteries (MAPCAs) is an uncommon form of congenital heart disease. As more patients with congenital heart disease live to adulthood, the objective of this article was to review the long-term results of this specific population. Methods A review of the PubMed database was performed using pertinent key words (pulmonary atresia, tetralogy of Fallot, conduit, right ventricle-pulmonary artery) concentrating on studies from 1990-present and published in English. Most studies of pulmonary atresia-ventricular septal defect patients included those with and without MAPCAs. Analysis included examination of the entire cohort, consideration of the proportion of patients with MAPCAs, and any subgroup analysis of the patients without MAPCAs. Results Survival is approximately 80% at ten years and is improved with complete repair and larger pulmonary arteries. Some studies have found genetic syndromes and extracardiac anomalies to impact survival, while others have not. Incomplete repair has been shown to be associated with worse survival. Independent of initial management strategy, patients with pulmonary atresia and ventricular septal defects without MAPCAs require repeat intervention on the right ventricular outflow tract. Hypoplastic pulmonary arteries have been shown to be a risk factor for reintervention, and decreased conduit durability has been shown with younger age at implantation of conduit. Conclusions Long-term outcomes have improved for patients with pulmonary atresia-ventricular septal defect without MAPCAs, with complete repair and adequate pulmonary arteries favorable for survival. Long-term outcomes include reinterventions, both catheter-based and surgical, predominantly on the right ventricular outflow tract.
Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer.
Hendrickson, Andrea E. Wahner , Foster, Nathan R. , Clasemann, Tracy, Grudem, Megan E. , Klampe, Carolyn M., Block, Matthew S. , Jatoi, Aminah , Weroha, Saravut J., Choong, Grace M. , Flickinger, Lynn M. , Ashley, Gary W. , Langecker, P., Santi, Daniel V. , Yadav, Siddhartha , Kaufmann, Scott H.

Journal of Clinical Oncology | July 23, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS5630-TPS5630

10.1200/jco.2024.42.16_suppl.tps5630 Get It

TPS5630 Background: Platinum-resistant ovarian cancer (PROC) portends a poor prognosis and, although treatments are available, response rates are low. Previous studies have demonstrated that DNA topoisomerase I (TOP1) inhibitors exhibit clinical activity in PROC. Irinotecan also has a 15-25% response rate in some studies of platinum-resistant epithelial ovarian cancer but does not have FDA approval for this indication. Additional studies in preclinical models suggest that TOP1 poisons are more active if administered at low doses on prolonged schedules. PLX038 is a long-acting prodrug of the potent TOP1 inhibitor SN-38. In PLX038, SN-38 is covalently conjugated to circulating polyethylene glycol and is slowly released at a constant rate to provide the active agent with a long half-life, a low Cmax and very high exposure – important facets for optimal safety and efficacy of this drug. Further, in preclinical studies the nanoparticle prodrug accumulates and is retained in tumors, where it slowly releases the SN-38. Methods: This single arm, phase 2 clinical trial is open at Mayo Clinic in Rochester, MN. The primary endpoint is overall response rate and secondary endpoints include progression-free survival and assessment of tolerability of PLX038. Correlative goals include i) measurement of TOP1-DNA covalent complexes in tumor biopsies and circulating tumor cells to assess successful target engagement; ii) assessment of homologous recombination status and SLFN11 expression for correlation with tumor response rate; and iii) pharmacokinetics of SN-38 and SN-38G as well as their association with GI toxicity. Assessment of gut microbiota and association with GI toxicity profile are also being investigated. Eligible patients include women with platinum resistant high grade serous ovarian, primary peritoneal, and fallopian tube cancer who have received fewer than two prior chemotherapy regimens in the platinum-resistant setting. All patients must have an ECOG performance status of 0, 1, or 2 and adequate bone marrow, renal, and hepatic function. As of January 31, 2024, 12 of planned 37 patients have enrolled. Clinical trial information: NCT05465941 .
Neonatal intestinal colonization of Streptococcus agalactiae and the multiple modes of protection limiting translocation
Greenfield, Kara G , Harlow, Olivia S., Witt, Lila T. , Dziekan, Evelyn M. , Tamar, Christian , Meier, Josephine, Brumbaugh, Jane E. , Levy, Emily R. , Knoop, Kathryn A. , Tamar, Christian R , Levy, Emily R , Knoop, Kathryn A , Brumbaugh, Jane E

Gut Microbes | July 23, 2024 | Volume: 16 | Issue: 1 | Pages: No page available

10.1080/19490976.2024.2379862 | PMID 39042143 Get It

A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Using Multiple Daily Injections of Insulin or Automated Insulin Delivery
Hirsch, Irl B., Beck, Roy W. , Marak, Martin Chase , Calhoun, Peter , Mottalib, Adham , Salhin, Amna, Manessis, Anastasios , Bhargava, Anuj , Thorsell, Ashley, Atakov-Castillo, Astrid , Bode, Bruce W., Levister, Camilla, Donahue, Cassandra, Cordero, Christian, Beatson, Christie , Langel, Christine R., Jacobson, Christopher , Kurek, Corey, Cruse, Dana, Pickering, David, Tamarez, Denisa, Desjardins, Donna, O’Malley, Grenye , Aktürk, Halis Kaan , Diner, Jamie, Baran, Jesica D., Ruedy, Katrina J., Codorniz, Kevin , Klein, Klara R. , Castorino, Kristin , Jordan, L.F., Kipnes, Mark, Church, Mei Mei , Raskin, Philip, Nguyen, Quang T., Weinstock, Ruth S. , Rizvi, Shafaq, Bzdick, Suzan, Rodriguez, Tahereh Ghorbani, Salah, Tareq , Blevins, Thomas , Kudva, Yogish C. , Haider, Zehra, Group, INHALE-3 Study, Bode, Bruce W., Ownby, Jonathan G., Johnson, Joseph H., Ruiz, Adriana, Stephens, Nashia, Maxson, Amanda, Beatson, Christie, Mason, E E , Steenkamp, Devin W., Wolpert, Howard , Sullivan, Asya, Salhin, Amna, Copple, Tina, Beltran, Stephanie, Ryan, Terri, O’Malley, Grenye, Tamarez, Denisa, Ipek, Aslihan, Burke, Christine, Langel, Christine, Bauman, Shannon , Haight, Cristina, Bohr, A., Badri, Marwa Al, Nguyen, Loida, Cordero, Christian, Migliozzi, Brittney, Reid, Corey, Kaur, Ravinder Jeet , Livingood, Daine, Cruse, Dana, Kravarusic, Jelena, Coyne, Kasey, Herrmann, Stefanie, Fronczyk, Evelyn, McKillop, Lorcan, Hyatt, Jamie, Patruno, Maria, Shuirman, Maggie, Cobb, Brandon, Watt, Olivia, Casaubon, Luis, Espinosa, Valerie, Pandit, Keta, Perez, Jennifer, Armstrong, Chloe, Martinez-Arredondo, Maritza, Stewart, Ana, Rodriguez, Tahereh Ghorbani, Young, Laura , Kass, Alexander, Fulghum, Karla, Jordan, Lin, Shao, Baomei, Baran, Jesica, Mandava, Patali, Holod, Rosanna, Kaiserman, Kevin B. , Ulloa, Johanna, Pleitez, Jennifer, Sylvan, Joey, Badgett, Lynn, Borgman, Sarah, Frey, Sarah, Mba-Oduwusi, Nnenna, Miller, Paige , Fults, Ashleigh, Marak, Martin, Pritchard, Rosa, Dolzhenko, E. N. , Gabrielson, Deanna, Brown, Sue A. , Ahmann, Andrew , Bergenstal, Richard M. , Levy, Carol J , Steenkamp, Devin W , Aleppo, Grazia , Akturk, Halis K , Klein, Klara R , Castorino, Kristin , Church, Mei Mei , Hamdy, Osama , Weinstock, Ruth S , Salah, Tareq , Kudva, Yogish C. , Beck, Roy W , Calhoun, Peter , Coviello, Andrea D. , Bode, Bruce W., Levy, Carol J. , Donahue, Cassandra, Aleppo, Grazia , Buse, John B. , Nguyen, Quang T., Lee, Scott Jeffery , Group, INHALE-3 Study, Bode, Bruce W., Beatson, Christie, Mason, Emma, Steenkamp, Devin W., Salhin, Amna, O’Malley, Grenye, Bauman, Shannon, Dhaver, Shilton , Nguyen, Quang T., Cordero, Christian, Cruse, Dana, Johnson, Olivia, Rodriguez, Tahereh Ghorbani, Miller, Paige, McCarthy, Chris

Diabetes Care | July 23, 2024 | Volume: 47 | Issue: 9 | Pages: 1682-1687

10.2337/dc24-0838 | PMID 39042575 Get It

OBJECTIVE To compare postprandial glucose excursions following a bolus with inhaled technosphere insulin (TI) or subcutaneous rapid-acting analog (RAA) insulin. RESEARCH DESIGN AND METHODS A meal challenge was completed by 122 adults with type 1 diabetes who were using multiple daily injections (MDI), a nonautomated pump, or automated insulin delivery (AID) and who were randomized to bolus with their usual RAA insulin (n = 61) or TI (n = 61). RESULTS The primary outcome, the treatment group difference in area under the curve for glucose >180 mg/dL over 2 h, was less with TI versus RAA (adjusted difference −12 mg/dL, 95% CI −22 to −2, P = 0.02). With TI, the glucose excursion was smaller (P = 0.01), peak glucose lower (P = 0.01), and time to peak glucose shorter (P = 0.006). Blood glucose <70 mg/dL occurred in one participant in each group. CONCLUSIONS Postmeal glucose excursion was smaller with TI than with RAA insulin in a cohort that included both AID and MDI users.
Vitamin D insufficiency in CLL: a modifiable prognostic factor?
Parikh, Sameer A. , Shanafelt, Tait D. , Parikh, Sameer A , Shanafelt, Tait D

Blood Advances | July 23, 2024 | Volume: 8 | Issue: 14 | Pages: 3838-3839

10.1182/bloodadvances.2024013428 | PMID 39042381 Get It

Resolving the 22q11.2 deletion using CTLR-Seq reveals chromosomal rearrangement mechanisms and individual variance in breakpoints
Zhou, Bo , Purmann, Carolin , Guo, Hanmin , Huang, Yi‐Ling , Meng, Qingxi , Greer, Stephanie , Wood, Raegan N., Ho, Marcus , Dohna, Heinrich zu , Abyzov, Alexej , Hallmayer, Joachim , Wong, Wing Hung , Ji, Hanlee P. , Urban, Alexander E. , Roychowdhury, Tanmoy , Wong, Wing H , Ji, Hanlee P , Zhou, Bo , Abyzov, Alexej , Shin, Gi Won , Pattni, Reenal

Proceedings of the National Academy of Sciences | July 23, 2024 | Volume: 121 | Issue: 31 | Pages: No page available

10.1073/pnas.2322834121 | PMID 39042694 Get It

We developed a generally applicable method, CRISPR/Cas9-targeted long-read sequencing (CTLR-Seq), to resolve, haplotype-specifically, the large and complex regions in the human genome that had been previously impenetrable to sequencing analysis, such as large segmental duplications (SegDups) and their associated genome rearrangements. CTLR-Seq combines in vitro Cas9-mediated cutting of the genome and pulse-field gel electrophoresis to isolate intact large (i.e., up to 2,000 kb) genomic regions that encompass previously unresolvable genomic sequences. These targets are then sequenced (amplification-free) at high on-target coverage using long-read sequencing, allowing for their complete sequence assembly. We applied CTLR-Seq to the SegDup-mediated rearrangements that constitute the boundaries of, and give rise to, the 22q11.2 Deletion Syndrome (22q11DS), the most common human microdeletion disorder. We then performed de novo assembly to resolve, at base-pair resolution, the full sequence rearrangements and exact chromosomal breakpoints of 22q11.2DS (including all common subtypes). Across multiple patients, we found a high degree of variability for both the rearranged SegDup sequences and the exact chromosomal breakpoint locations, which coincide with various transposons within the 22q11.2 SegDups, suggesting that 22q11DS can be driven by transposon-mediated genome recombination. Guided by CTLR-Seq results from two 22q11DS patients, we performed three-dimensional chromosomal folding analysis for the 22q11.2 SegDups from patient-derived neurons and astrocytes and found chromosome interactions anchored within the SegDups to be both cell type-specific and patient-specific. Lastly, we demonstrated that CTLR-Seq enables cell-type specific analysis of DNA methylation patterns within the deletion haplotype of 22q11DS.
Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations
Shah, Osama Shiraz , Nasrazadani, Azadeh , Foldi, Julia , Kleer, Celina G. , McAuliffe, Priscilla F. , Johnston, Tyler J., Silva, Edaise M. da , Selenica, Pier, Dopeso, Higinio , Pareja, Fresia , Weigelt, Britta , Reis-Filho, Jorge S., Oesterreich, Steffi , Kleer, Celina G , McAuliffe, Priscilla F , Johnston, Tyler J , da Silva, Edaise M , Dopeso, Higinio , Bhargava, Rohit , Lucas, Peter C , Lee, Adrian V , Oesterreich, Steffi , Shah, Osama , Atkinson, Jennifer M. , Stallaert, Wayne , Mandelker, Diana L. , Reis-Filho, Jorge S , Lucas, Peter C. , Lee, Adrian V.

Proceedings of the National Academy of Sciences | July 23, 2024 | Volume: 121 | Issue: 31 | Pages: No page available

10.1073/pnas.2322068121 | PMID 39042692 Get It

Mixed invasive ductal and lobular carcinoma (MDLC) is a rare histologic subtype of breast cancer displaying both E-cadherin positive ductal and E-cadherin negative lobular morphologies within the same tumor, posing challenges with regard to anticipated clinical management. It remains unclear whether these distinct morphologies also have distinct biology and risk of recurrence. Our spatially resolved transcriptomic, genomic, and single-cell profiling revealed clinically significant differences between ductal and lobular tumor regions including distinct intrinsic subtype heterogeneity – e.g., MDLC with triple-negative breast cancer (TNBC) or basal ductal and estrogen receptor positive (ER+) luminal lobular regions, distinct enrichment of cell cycle arrest/senescence and oncogenic (ER and MYC ) signatures, genetic and epigenetic CDH1 inactivation in lobular but not ductal regions, and single-cell ductal and lobular subpopulations with unique oncogenic signatures further highlighting intraregional heterogeneity. Altogether, we demonstrated that the intratumoral morphological/histological heterogeneity within MDLC is underpinned by intrinsic subtype and oncogenic heterogeneity which may result in prognostic uncertainty and therapeutic dilemma.
Outcomes in Stage IIA vs. Stage IIB/III in the PALLAS Trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
Dueck, Amylou C. , Martín, Miguel, Burstein, H.J., Zdenkowski, Nick, Bellet-Ezquerra, M., Miller, Kathy, Lake, Diana, Rubovsky, Gabor, Cameron, D. , Singer, Christian, Nowecki, Zbigniew , Iwata, Hiroji, Parraga, Kepa Amilano, Rugo, Hope, Steger, Guenther G. , Theall, Kathy Puyana, Lu, Ray Dongrui, O’Brien, Patrick, Fesl, Christian , Bellet, Meritxell , Dueck, A. C. , DeMichele, Angela , Hlauschek, Dominik , Martı́n, Miguel , Pfeiler, GH, Zdenkowski, Nicholas , Wolff, Antonio C. , Winer, Eric P. , Balić, Marija , Miller, Kathy L. , Colleoni, Marco , Rubovsky, Gabor , Cameron, D., Balko, Justin M. , Singer, Christian F. , Iwata, Hiroji , Wolmark, Norman , Parraga, Kepa Amillano, Traina, Tiffany A , Werutsky, Gustavo , Czajkowska, D., Metzger, Otto , El-Abed, Sarra , Theall, K. P., O’Brien, P. , Mayer, E., Gnant, Michael

No container title available | July 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4612404/v1 Get It

Abstract Background The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy reduces breast cancer recurrence. This pre-specified analysis was conducted to determine whether adjuvant palbociclib benefited patients diagnosed with lower risk stage IIA disease compared to those with higher stage disease. Methods PALLAS was an international, multicenter, randomized, open-label, phase III trial, representing a public-private partnership between Pfizer, the Austrian Breast Cancer Study Group and, the U.S. ALLIANCE Foundation. Patients diagnosed with stage II-III, hormone-receptor-positive, HER2/neu negative breast cancer who were within 12 months of diagnosis, and had completed all definitive therapy aside from endocrine therapy, which was started within 6 months prior to study entry. All patients were required to submit a formalin-fixed paraffin-embedded (FFPE) tumor block. Patients were randomly assigned 1:1 to receive standard adjuvant endocrine therapy (of physicians’ choice) for at least 5 years with or without 2 years of Palbociclib, administered orally at a starting dose of 125 mg daily, given for 21 days followed by a 7-day break. Results A total of 5,796 patients with HR+/HER2- early breast cancer (including 1,010 with stage IIA) were enrolled. Median follow-up was 50 months for stage IIA patients and 43.1 months overall. In the stage IIA cohort, four-year iDFS in the palbociclib arm was 92.9% versus 92.1% for ET alone (HR 0.75, 95%CI 0.48–1.19, p = 0.23). There was no differential benefit by histologic grade, chemotherapy receipt, age, or anatomic/clinical risk. Additionally, no benefit to palbociclib was seen in this cohort in invasive breast cancer-free survival (iBCFS), locoregional relapse-free survival (LRFS), distant relapse-free survival (DRFS), or overall survival (OS). For the stage IIB/III patients, 4-year iDFS was 85.3% for palbociclib + ET versus 83.6% for ET alone (HR 0.91, 95% CI 0.77–1.07, p = 0.24). Conclusions and Relevance: While there were substantial differences in outcome for stage IIA versus IIB/III patients at 4 years of follow-up, the addition of 2 years of palbociclib did not improve outcomes for patients, regardless of stage. Trial Registration: The study was registered on Clinicaltrials.gov on July 31, 2015, and was assigned the clinical trial number (NCT02513394).
Neurosurgical bleeding in platelet storage pool disorder: a case report
Alcorn, Kirsten, Fesler, Joanna, Landis, Daniel, Litvack, Zachary, Hegerova, Livia , Pierre, Clifford A. , Chen, Dong , Konkle, Barbara A.

Platelets | July 23, 2024 | Volume: 35 | Issue: 1 | Pages: No page available

10.1080/09537104.2024.2380374 | PMID 39041657 Get It

Spatial Computing Opportunities in Biomedical Decision Support: The Atlas-EHR Vision
Farhadloo, Majid , Sharma, Arun , Shekhar, Shashi , Markovic, Svetomir N. , Markovic, Svetomir , Shekhar, Shashi

ACM Transactions on Spatial Algorithms and Systems | July 23, 2024 | Volume: 10 | Issue: 3 | Pages: 1-36

10.1145/3679201 Get It

We consider the problem of reducing the time that healthcare professionals need to understand the patient’s medical history through the next generation of biomedical decision support. This problem is societally important because it has the potential to improve healthcare quality and patient outcomes. However, navigating electronic health records (EHR) is challenging due to high patient-doctor ratios, potentially long medical histories, urgency of treatment for some medical conditions, and patient variability. The current EHR systems provide only a longitudinal view of patient medical history, which is time-consuming to browse, and doctors often need to engage nurses, residents, and others for initial analysis. To overcome this limitation, we envision an alternative spatial representation of patient histories (e.g., electronic health records) and other biomedical data in the form of Atlas-EHR. Just like Google Maps, which allows a global, national, regional, and local view, Atlas-EHR can start with an overview of the patient’s anatomy and history before drilling down to spatially anatomical subsystems, their individual components, or subcomponents. Atlas-EHR presents a compelling opportunity for spatial computing since healthcare is almost a fifth of the US economy. However, traditional spatial computing designed for geographic use cases (e.g., navigation, land survey, and mapping) faces many hurdles in the biomedical domain. This article presents several open research questions under this theme in five broad areas of spatial computing.